Get started
Alto Neuroscience, Inc.Alto Neuroscience, Inc.Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ANRO chart


Full chart

ANRO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪102.22 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.13 USD
Net income (FY)
‪−36.30 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪21.95 M‬
Beta (1Y)
2.52

Employees


Employees (FY)
63
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−576.27 K‬ USD

About Alto Neuroscience, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Amit Etkin
Website
altoneuroscience.com
Headquarters
Mountain View
Founded
2019
FIGI
BBG00WYFS6R5
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ANRO news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ANRO is 3.89 USD — it has increased by 1.07% in the past 24 hours. Watch Alto Neuroscience, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Alto Neuroscience, Inc. stocks are traded under the ticker ANRO.
ANRO stock has risen by 1.88% compared to the previous week, the month change is a −18.14% fall, over the last year Alto Neuroscience, Inc. has showed a −82.34% decrease.
We've gathered analysts' opinions on Alto Neuroscience, Inc. future price: according to them, ANRO price has a max estimate of 18.00 USD and a min estimate of 4.00 USD. Watch ANRO chart and read a more detailed Alto Neuroscience, Inc. stock forecast: see what analysts think of Alto Neuroscience, Inc. and suggest that you do with its stocks.
ANRO reached its all-time high on Feb 5, 2024 with the price of 24.00 USD, and its all-time low was 3.61 USD and was reached on Nov 5, 2024. View more price dynamics on ANRO chart.
See other stocks reaching their highest and lowest prices.
ANRO stock is 4.28% volatile and has beta coefficient of 2.52. Track Alto Neuroscience, Inc. stock price on the chart and check out the list of the most volatile stocks — is Alto Neuroscience, Inc. there?
Today Alto Neuroscience, Inc. has the market capitalization of ‪102.22 M‬, it has decreased by −2.57% over the last week.
Yes, you can track Alto Neuroscience, Inc. financials in yearly and quarterly reports right on TradingView.
Alto Neuroscience, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
ANRO earnings for the last quarter are −0.62 USD per share, whereas the estimation was −0.65 USD resulting in a 4.62% surprise. The estimated earnings for the next quarter are −0.65 USD per share. See more details about Alto Neuroscience, Inc. earnings.
Alto Neuroscience, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ANRO net income for the last quarter is ‪−16.78 M‬ USD, while the quarter before that showed ‪−16.03 M‬ USD of net income which accounts for −4.70% change. Track more Alto Neuroscience, Inc. financial stats to get the full picture.
No, ANRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 63.00 employees. See our rating of the largest employees — is Alto Neuroscience, Inc. on this list?
Like other stocks, ANRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alto Neuroscience, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alto Neuroscience, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alto Neuroscience, Inc. stock shows the sell signal. See more of Alto Neuroscience, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.